Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Holia Hatoum-Mokdad is active.

Publication


Featured researches published by Holia Hatoum-Mokdad.


Bioorganic & Medicinal Chemistry Letters | 1999

Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors.

Jacques Dumas; David R. Brittelli; Jinshan Chen; Brian R. Dixon; Holia Hatoum-Mokdad; Gerhard Konig; Robert Sibley; James Witowsky; Stephen Wong

Cathepsin D, a lysosomal aspartyl protease, has been implicated in the pathology of Alzheimers disease as well as breast and ovarian cancer. A weakly active cathepsin D inhibitor was identified by high throughput screening. Subsequent optimization led to the discovery of a new class of small molecule inhibitors of this enzyme, culminating with the sulfonamide 13 (IC50 = 250 nM).


Bioorganic & Medicinal Chemistry Letters | 2000

1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors

Jacques Dumas; Holia Hatoum-Mokdad; Robert Sibley; Bernd Riedl; William J. Scott; Mary Katherine Monahan; Timothy B. Lowinger; Catherine Brennan; Reina Natero; Tiffany Turner; Jeffrey S Johnson; Robert W. Schoenleber; Ajay Bhargava; Scott Wilhelm; Timothy J Housley; Gerald Ranges; Alka Shrikhande

Inhibitors of the MAP kinase p38 are potentially useful for the treatment of arthritis and osteoporosis. Several 2,3-dichlorophenyl ureas were identified as small-molecule inhibitors of p38 by a combinatorial chemistry effort. Optimization for cellular potency led to the discovery of a new class of potent and selective p38 kinase inhibitors, exemplified by the 1-phenyl-5-pyrazolyl urea 7 (IC50 = 13 nM).


Bioorganic & Medicinal Chemistry Letters | 2001

Discovery and Parallel Synthesis of a New Class of Cathepsin K Inhibitors

Roger A. Smith; Ajay Bhargava; Christopher Browe; Jinshan Chen; Jacques Dumas; Holia Hatoum-Mokdad; Romulo Romero

Peptidomimetic aminomethyl ketones have been identified as a new class of cathepsin K inhibitors. Traditional and high-speed parallel synthesis techniques were applied to investigate this series. Structure-activity relationships were established, and certain analogues were characterized with IC(50) values in the range 200-500 nM.


Archive | 1998

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

Scott Miller; Martin Osterhout; Jacques Dumas; Uday Khire; Timothy B. Lowinger; William J. Scott; Roger A. Smith; Jill E. Wood; David E. Gunn; Holia Hatoum-Mokdad; Marell Rodriguez; Robert Sibley; Ming Wang; Tiffany Turner; Catherine Brennan


Archive | 1998

Inhibition of raf kinase using substituted heterocyclic ureas

Jacques Dumas; Uday Khire; Timothy B. Lowinger; Holger Paulsen; Bernd Riedl; William J. Scott; Roger A. Smith; Jill E. Wood; Holia Hatoum-Mokdad; Jeffrey Johnson; Wendy Lee; Aniko Redman; Robert Sibley; Joel Renick


Archive | 1998

INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS

Jacques Dumas; Uday Khire; Timothy B. Lowinger; Holger Paulsen; Bernd Riedl; William J. Scott; Roger A. Smith; Jill E. Wood; Holia Hatoum-Mokdad; Jeffrey S Johnson; Wendy Lee; Aniko Redman


Archive | 1998

INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS

Jacques Dumas; Uday Khire; Timothy B. Lowinger; Bernd Riedl; William J. Scott; Roger A. Smith; Jill E. Wood; Holia Hatoum-Mokdad; Jeffrey S Johnson; Aniko Redman; Robert Sibley


Archive | 1998

Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas

Jacques Dumas; Uday Khire; Timothy B. Lowinger; Bernd Riedl; William J. Scott; Roger A. Smith; Jill E. Wood; Holia Hatoum-Mokdad; Jeffrey S Johnson; Aniko Redman; Robert Sibley


Archive | 2002

Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas

Jacques Dumas; Bernd Riedl; Uday Khire; Robert Sibley; Holia Hatoum-Mokdad; Mary-Katherine Monahan; David E. Gunn; Timotthy B. Lowinger; William J. Scott; Roger A. Smith; Jill E. Wood


Archive | 2002

2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors

Julie Dixon; William J. Scott; Jacques Dumas; Catherine Brennan; Holia Hatoum-Mokdad

Collaboration


Dive into the Holia Hatoum-Mokdad's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge